Sarafan ChEM-H


Showing 101-150 of 181 Results

  • Lingyin Li

    Lingyin Li

    Associate Professor of Biochemistry

    BioDr. Li is an associate professor in the Biochemistry Department and ChEM-H Institute at Stanford since 2015. Her lab works on understanding biochemical mechanisms of innate immunity and harnessing it to treat cancer. She majored in chemistry at University of Science and Technology of China and graduated with a B. En in 2003. She then trained with Dr. Laura Kiessling, a pioneer in chemical biology, at University of Wisconsin-Madison and graduated with a Ph.D in chemistry in 2010. She obtained her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology.

  • Michael Lin

    Michael Lin

    Associate Professor of Neurobiology, of Bioengineering and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsOur lab applies biochemical and engineering principles to the development of protein-based tools for investigating biology in living animals. Topics of investigation include fluorescent protein-based voltage indicators, synthetic light-controllable proteins, bioluminescent reporters, and applications to studying animal models of disease.

  • Kyle Loh

    Kyle Loh

    Assistant Professor of Developmental Biology (Stem Cell)

    Current Research and Scholarly InterestsWe have developed a strategy to generate fairly pure populations of various human tissue progenitors in a dish from embryonic stem cells (ESCs). We have delineated the sequential lineage steps through which ESCs diversify into various tissues, and in so doing, developed methods to exclusively induce certain fates at the expense of others. The resultant pure populations of tissue progenitors are the fundamental building blocks for regenerative medicine.

  • Jonathan Z. Long

    Jonathan Z. Long

    Assistant Professor of Pathology

    BioDr. Jonathan Long is an Assistant Professor of Pathology and an Institute Scholar of Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). Prior to arriving to Stanford in 2018, Dr. Long completed his Ph.D. in Chemistry at Scripps Research with Benjamin F. Cravatt and his postdoctoral work at Harvard Medical School/Dana-Farber Cancer Institute with Bruce M. Spiegelman. His contributions in the areas of lipid biochemistry and energy homeostasis have been recognized by numerous awards from the National Institutes of Health and the American Diabetes Association. At Stanford, the Long laboratory studies signaling pathways in mammalian energy metabolism. The long-term goal of this work is to discover new molecules and pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases.

  • Sharon R. Long

    Sharon R. Long

    William C. Steere, Jr. - Pfizer Inc. Professor of Biological Sciences and Professor, by courtesy, of Biochemistry

    Current Research and Scholarly InterestsBiochemistry, genetics and cell biology of plant-bacterial symbiosis

  • Anson Lowe

    Anson Lowe

    Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus

    Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.

  • Sydney X. Lu

    Sydney X. Lu

    Assistant Professor of Medicine (Hematology)

    BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
    Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
    The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.

    Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
    1) normal and pathologic immunity and immunotherapy
    2) cancer biology
    3) normal and malignant hematopoiesis

  • Liqun Luo

    Liqun Luo

    Ann and Bill Swindells Professor and Professor, by courtesy, of Neurobiology

    Current Research and Scholarly InterestsWe study how neurons are organized into specialized circuits to perform specific functions and how these circuits are assembled during development. We have developed molecular-genetic and viral tools, and are combining them with transcriptomic, proteomic, physiological, and behavioral approaches to study these problems. Topics include: 1) assembly of the fly olfactory circuit; 2) assembly of neural circuits in the mouse brain; 3) organization and function of neural circuits; 4) Tool development.

  • Vinit Mahajan, MD, PhD

    Vinit Mahajan, MD, PhD

    Professor of Ophthalmology

    Current Research and Scholarly InterestsOur focus is the development of personalized medicine for eye diseases through translation of our discoveries in proteomics, genomics, and phenomics in humans, mice and tissue culture models.

  • Nicole M. Martinez

    Nicole M. Martinez

    Assistant Professor of Chemical and Systems Biology and of Developmental Biology

    Current Research and Scholarly InterestsThe Martinez lab studies RNA regulatory mechanisms that control gene expression. We focus on mRNA processing, RNA modifications and their roles in development and disease.

  • Michaëlle Ntala Mayalu

    Michaëlle Ntala Mayalu

    Assistant Professor of Mechanical Engineering

    BioDr. Michaëlle N. Mayalu is an Assistant Professor of Mechanical Engineering. She received her Ph.D., M.S., and B.S., degrees in Mechanical Engineering at the Massachusetts Institute of Technology. She was a postdoctoral scholar at the California Institute of Technology in the Computing and Mathematical Sciences Department. She was a 2017 California Alliance Postdoctoral Fellowship Program recipient and a 2019 Burroughs Wellcome Fund Postdoctoral Enrichment Program award recipient.

    Dr. Michaëlle N. Mayalu's area of expertise is in mathematical modeling and control theory of synthetic biological and biomedical systems. She is interested in the development of control theoretic tools for understanding, controlling, and predicting biological function at the molecular, cellular, and organismal levels to optimize therapeutic intervention.

    She is the director of the Mayalu Lab whose research objective is to investigate how to optimize biomedical therapeutic designs using theoretical and computational approaches coupled with experiments. Initial project concepts include: i) theoretical and experimental design of bacterial "microrobots" for preemptive and targeted therapeutic intervention, ii) system-level multi-scale modeling of gut associated skin disorders for virtual evaluation and optimization of therapy, iii) theoretical and experimental design of "microrobotic" swarms of engineered bacteria with sophisticated centralized and decentralized control schemes to explore possible mechanisms of pattern formation. The experimental projects in the Mayalu Lab utilize established techniques borrowed from the field of synthetic biology to develop synthetic genetic circuits in E. coli to make bacterial "microrobots". Ultimately the Mayalu Lab aims to develop accurate and efficient modeling frameworks that incorporate computation, dynamical systems, and control theory that will become more widespread and impactful in the design of electro-mechanical and biological therapeutic machines.

  • Nicholas Melosh

    Nicholas Melosh

    Professor of Materials Science and Engineering

    BioThe Melosh group explores how to apply new methods from the semiconductor and self-assembly fields to important problems in biology, materials, and energy. We think about how to rationally design engineered interfaces to enhance communication with biological cells and tissues, or to improve energy conversion and materials synthesis. In particular, we are interested in seamlessly integrating inorganic structures together with biology for improved cell transfection and therapies, and designing new materials, often using diamondoid molecules as building blocks.
    My group is very interested in how to design new inorganic structures that will seamless integrate with biological systems to address problems that are not feasible by other means. This involves both fundamental work such as to deeply understand how lipid membranes interact with inorganic surfaces, electrokinetic phenomena in biologically relevant solutions, and applying this knowledge into new device designs. Examples of this include “nanostraw” drug delivery platforms for direct delivery or extraction of material through the cell wall using a biomimetic gap-junction made using nanoscale semiconductor processing techniques. We also engineer materials and structures for neural interfaces and electronics pertinent to highly parallel data acquisition and recording. For instance, we have created inorganic electrodes that mimic the hydrophobic banding of natural transmembrane proteins, allowing them to ‘fuse’ into the cell wall, providing a tight electrical junction for solid-state patch clamping. In addition to significant efforts at engineering surfaces at the molecular level, we also work on ‘bridge’ projects that span between engineering and biological/clinical needs. My long history with nano- and microfabrication techniques and their interactions with biological constructs provide the skills necessary to fabricate and analyze new bio-electronic systems.


    Research Interests:
    Bio-inorganic Interface
    Molecular materials at interfaces
    Self-Assembly and Nucleation and Growth

  • Timothy Meyer

    Timothy Meyer

    Stanford University Professor of Nephrology, Emeritus

    Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.

  • Paul Salomon Mischel

    Paul Salomon Mischel

    Professor of Pathology and, by courtesy, of Neurosurgery

    Current Research and Scholarly InterestsMy research bridges cancer genetics, signal transduction and cellular metabolism as we aim to understand the molecular mechanisms that drive cancer development, progression, and drug resistance. We have made a series of discoveries that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance.

  • W. E. Moerner

    W. E. Moerner

    Harry S. Mosher Professor and Professor, by courtesy, of Applied Physics

    Current Research and Scholarly InterestsLaser spectroscopy and microscopy of single molecules to probe biological systems, one biomolecule at a time. Primary thrusts: fluorescence microscopy far beyond the optical diffraction limit (PALM/STORM/STED), methods for 3D optical microscopy in cells, and trapping of single biomolecules in solution for extended study. We explore protein localization patterns in bacteria, structures of amyloid aggregates in cells, signaling proteins in the primary cilium, and dynamics of DNA and RNA.

  • Denise M. Monack

    Denise M. Monack

    Martha Meier Weiland Professor in the School of Medicine

    Current Research and Scholarly InterestsThe primary focus of my research is to understand the genetic and molecular mechanisms of intracellular bacterial pathogenesis. We use several model systems to study complex host-pathogen interactions in the gut and in immune cells such as macrophages and dendritic cells. Ultimately we would like to understand how Salmonella persists within certain hosts for years in the face of a robust immune response.

  • David Myung, MD, PhD

    David Myung, MD, PhD

    Associate Professor of Ophthalmology and, by courtesy, of Chemical Engineering

    Current Research and Scholarly InterestsNovel biomaterials to reconstruct the wounded cornea
    Mesenchymal stem cell therapy for corneal and ocular surface regeneration
    Engineered biomolecule therapies for promote corneal wound healing

    Telemedicine in ophthalmology

  • Lauren O'Connell

    Lauren O'Connell

    Assistant Professor of Biology

    Current Research and Scholarly InterestsThe O'Connell lab studies how genetic and environmental factors contribute to biological diversity and adaptation. We are particularly interested in understanding (1) how behavior evolves through changes in brain function and (2) how animal physiology evolves through repurposing existing cellular components.

  • Sergiu P. Pasca

    Sergiu P. Pasca

    Bonnie Uytengsu and Family Director of Stanford Brain Organogenesis and Associate Professor of Psychiatry and Behavioral Sciences (Sleep Medicine)

    Current Research and Scholarly InterestsA critical challenge in understanding the intricate programs underlying development, assembly and dysfunction of the human brain is the lack of direct access to intact, functioning human brain tissue for detailed investigation by imaging, recording, and stimulation.
    To address this, we are developing bottom-up approaches to generate and assemble, from multi-cellular components, human neural circuits in vitro and in vivo.
    We introduced the use of instructive signals for deriving from human pluripotent stem cells self-organizing 3D cellular structures named brain region-specific spheroids/organoids. We demonstrated that these cultures, such as the ones resembling the cerebral cortex, can be reliably derived across many lines and experiments, contain synaptically connected neurons and non-reactive astrocytes, and can be used to gain mechanistic insights into genetic and environmental brain disorders. Moreover, when maintained as long-term cultures, they recapitulate an intrinsic program of maturation that progresses towards postnatal stages.
    We also pioneered a modular system to integrate 3D brain region-specific organoids and study human neuronal migration and neural circuit formation in functional preparations that we named assembloids. We have actively applied these models in combination with studies in long-term ex vivo brain preparations to acquire a deeper understanding of human physiology, evolution and disease mechanisms.
    We have carved a unique research program that combines rigorous in vivo and in vitro neuroscience, stem cell and molecular biology approaches to construct and deconstruct previously inaccessible stages of human brain development and function in health and disease.
    We believe science is a community effort, and accordingly, we have been advancing the field by broadly and openly sharing our technologies with numerous laboratories around the world and organizing the primary research conference and the training courses in the area of cellular models of the human brain.

  • Suzanne Pfeffer

    Suzanne Pfeffer

    Emma Pfeiffer Merner Professor of Medical Sciences

    Current Research and Scholarly InterestsThe major focuses of our research is to understand the molecular basis of inherited Parkinson's Disease (PD) and to elucidate the molecular mechanisms by which proteins and cholesterol are transported between specific membrane compartments. We focus on the LRRK2 kinase that is inappropriately activated in PD and how it phosphorylates Rab GTPases, blocking the formation of primary cilia in culture and specific regions of the brain.

  • Elizabeth Ponder

    Elizabeth Ponder

    Executive Director, Sarafan ChEM-H

    BioDr. Elizabeth Ponder joined Stanford ChEM-H in 2014 and is currently the Executive Director of Sarafan ChEM-H and the Stanford Innovative Medicines Accelerator (IMA). Dr. Ponder completed her Ph.D. and postdoctoral training at Stanford University in the laboratory of Dr. Matthew Bogyo. Her past work has included promoting public-private partnerships in the non-profit sector, managing multidisciplinary research in the higher education sector, and business development consulting in the for-profit biotech sector. Dr. Ponder joined ChEM-H from the University of California, Berkeley where she served as the Executive Director of the Henry Wheeler Center for Emerging & Neglected Diseases (CEND).

  • Matthew Porteus

    Matthew Porteus

    Sutardja Chuk Professor of Definitive and Curative Medicine

    BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.

  • Guillem Pratx

    Guillem Pratx

    Associate Professor of Radiation Oncology (Radiation Physics)

    Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.

  • Lei Stanley Qi

    Lei Stanley Qi

    Associate Professor of Bioengineering

    BioDr. Lei Stanley Qi is associate professor in the Department of Bioengineering, a faculty fellow in Stanford ChEM-H, and a Chan Zuckerberg Biohub Investigator. Dr. Qi is one major contributor to the development of CRISPR technologies for genome engineering. He developed the first use of nuclease-deactivated Cas9 (dCas9) for sequence-targeted gene regulation in prokaryotic and eukaryotic cells. His lab invents a broad CRISPR toolbox for manipulating the human genome, including technologies for gene regulation (CRISPRi and CRISPRa), epigenome engineering, live cell DNA/RNA imaging (LiveFISH), 3D genome manipulation (CRISPR-GO), CRISPR antivirals for SARS-CoV-2 (PAC-MAN), and miniature CRISPR (CasMINI) for gene therapy. His lab combines synthetic biology with genome engineering to study the function of the genome and develop novel gene therapy. He obtained B.S. in Physics from Tsinghua University, Ph.D. in Bioengineering from the University of California Berkeley, and was a UCSF Systems Biology Faculty Fellow. He joined the faculty at Stanford University in 2014.

  • Jianghong Rao

    Jianghong Rao

    Professor of Radiology (Molecular Imaging Program at Stanford) and, by courtesy, of Chemistry

    Current Research and Scholarly InterestsProbe chemistry and nanotechnology for molecular imaging and diagnostics

  • Julien Sage

    Julien Sage

    Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics
    On Partial Leave from 05/30/2022 To 08/28/2022

    Current Research and Scholarly InterestsWe investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.

  • Kathleen M. Sakamoto

    Kathleen M. Sakamoto

    Shelagh Galligan Professor in the School of Medicine

    Current Research and Scholarly InterestsMy research focuses on the molecular pathways that regulate normal and aberrant blood cell development, including acute leukemia and bone marrow failure syndromes. We are also studying novel drugs for treatment of cancer.

  • Julia Salzman

    Julia Salzman

    Associate Professor of Biomedical Data Science, of Biochemistry and, by courtesy, of Statistics

    Current Research and Scholarly Interestsstatistical computational biology focusing on splicing, cancer and microbes

  • Juan G. Santiago

    Juan G. Santiago

    Charles Lee Powell Foundation Professor

    Current Research and Scholarly Interestshttp://microfluidics.stanford.edu/Projects/Projects.html

  • Serena Sanulli

    Serena Sanulli

    Assistant Professor of Genetics

    Current Research and Scholarly InterestsWe study the organizing principles of the genome and how these principles regulate cell identity and developmental switches. We combine Biochemistry and Biophysical methods such as NMR and Hydrogen-Deuterium Exchange-MS with Cell Biology, and Genetics to explore genome organization across length and time scales and understand how cells leverage the diverse biophysical properties of chromatin to regulate genome function.

  • Ansuman Satpathy

    Ansuman Satpathy

    Assistant Professor of Pathology

    Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.

    We previously developed genome sequencing technologies that enable epigenetic studies in primary human immune cells from patients: 1) 3D enhancer-promoter interaction profiling (Nat Genet, 2017), 2) paired epigenome and T cell receptor (TCR) profiling in single cells (Nat Med, 2018), 3) paired epigenome and CRISPR profiling in single cells (Cell, 2019), and high-throughput single-cell ATAC-seq in droplets (Nature Biotech, 2019). We used these tools to study fundamental principles of the T cell response to cancer immunotherapy (PD-1 blockade) directly in cancer patient samples (Nature Biotech, 2019; Nat Med, 2019).

  • Elizabeth Sattely

    Elizabeth Sattely

    Associate Professor of Chemical Engineering

    BioPlants have an extraordinary capacity to harvest atmospheric CO2 and sunlight for the production of energy-rich biopolymers, clinically used drugs, and other biologically active small molecules. The metabolic pathways that produce these compounds are key to developing sustainable biofuel feedstocks, protecting crops from pathogens, and discovering new natural-product based therapeutics for human disease. These applications motivate us to find new ways to elucidate and engineer plant metabolism. We use a multidisciplinary approach combining chemistry, enzymology, genetics, and metabolomics to tackle problems that include new methods for delignification of lignocellulosic biomass and the engineering of plant antibiotic biosynthesis.